Zydus Cadila receives final approval for Apremilast
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
It is a recombinant nanoparticle protein-based vaccine
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
UFlex has committed close to US $ 10 million towards various initiatives at its overseas and Indian plants to repurpose plastic waste
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Subscribe To Our Newsletter & Stay Updated